Progress Toward Measles Elimination — South-East Asia Region, 2003–2013

Arun Thapa, MD1; Sudhir Khanal, MPH1; Umid Sharapov, MD2; Virginia Swezy, MPH1; Tika Sedai, MA1; Alya Dabbagh, PhD3; Paul Rota, PhD4; James L. Goodson, MPH2; Jeffrey McFarland, MD1 (Author affiliations at end of text)

In 2013, the 66th session of the Regional Committee of the World Health Organization (WHO) South-East Asia Region* adopted the goal of measles elimination and rubella and congenital rubella syndrome control† by 2020 after rigorous prior consultations (1–3). The recommended strategies include 1) achieving and maintaining ≥95% coverage with 2 doses of measles- and rubella-containing vaccine in every district through routine or supplementary immunization activities (SIAs)§; 2) developing and sustaining a sensitive and timely case-based measles surveillance system that meets recommended performance indicators¶; 3) developing and maintaining an accredited measles laboratory network; and 4) achieving timely identification, investigation, and response to measles outbreaks. This report updates previous reports and summarizes progress toward measles elimination in the South-East Asia Region during 2003–2013 (4). Within the region, coverage with the first dose of a measles-containing vaccine (MCV1) increased from 67% to 78%; an estimated 286 million children (95% of the target population) were vaccinated in SIAs; measles incidence decreased 73%, from 59 to 16 cases per million population; and estimated measles deaths decreased 63%. To achieve measles elimination in the region, additional efforts are needed in countries with <95% 2-dose routine MCV coverage, particularly in India and Indonesia, to strengthen routine immunization services, conduct periodic high-quality SIAs, and strengthen measles case-based surveillance and laboratory diagnosis of measles.

Immunization Activities

MCV1 was introduced in all 11 countries in the South-East Asia region before 2003. During 2003–2013, MCV1 was administered at age 9 months in all countries except Sri Lanka, where the age of administration was increased from 9 to 12 months in 2011 (Table 1). During 2003–2013, the number of countries in the region with a routine second dose of MCV (MCV2) increased from two to nine. The recommended age for administration for MCV2 varied by country and ranged from 15 months to 7 years. Countries report national and subnational coverage with MCV1 and MCV2 delivered through the routine immunization program to WHO and the United Nations Children’s Fund (UNICEF), which use data from administrative records (vaccine doses administered divided by the target population) and surveys reported by member states each year to estimate MCV1 and MCV2 coverage (5). Estimated MCV1 coverage increased in the region from 67% in 2003 to 78% in 2013; four countries reported ≥95% MCV1 coverage nationwide and in all districts in 2013 (Table 1, Figure). Estimated MCV2 coverage increased from 6% in 2003 to 53% in 2013; in 2013, estimated MCV2 coverage in three countries was ≥95%. During 2003–2013, measles SIAs were conducted in all countries except Thailand and reached 286 million children (95% of target population) (Table 2). Of the 39 SIAs, 16 (41%) achieved ≥95% administrative coverage.

Surveillance Activities

By 2013, measles surveillance with laboratory confirmation of suspected cases was implemented in all countries in the region. Bangladesh, Nepal, and Myanmar reported case-based measles surveillance data monthly to the WHO South-East Asia Regional Office, whereas other countries in the region reported aggregate measles surveillance data monthly (6). Five countries (Bangladesh, India, Indonesia, Myanmar, and Nepal) used the WHO-supported network of surveillance medical officers initially established for polio eradication to conduct measles surveillance (3). A measles-rubella laboratory network was established in the region by 2003, as an integral part of
Measles Incidence and Measles Virus Genotypes

From 2003 to 2013, annual measles incidence in the region decreased 73%, from 59 to 16 cases per million population. Five countries reported measles incidence of <5 cases per million in 2013, including three (Bhutan, North Korea, and India); 74% of reported cases were in Bangladesh, Bhutan, Nepal, Sri Lanka, and Thailand. By 2013, this regional laboratory network had expanded to include 34 proficient laboratories** with one regional reference laboratory in Thailand. All countries in the region except Timor-Leste had at least one proficient laboratory, including India (nine laboratories), Indonesia (four), and Thailand (13). In addition, Bangladesh, Bhutan, Nepal, Sri Lanka, and Thailand had also started sentinel surveillance for congenital rubella syndrome.

During 2003–2013, a total of 5,680 suspected measles outbreaks were reported in countries in the region, 5,166 (91%) of which were fully investigated.†† Among those investigated, 2,530 (49%) were laboratory-confirmed measles outbreaks, 2,530 (49%) were laboratory-confirmed measles outbreaks, 1,437 (28%) were laboratory-confirmed mixed measles and rubella outbreaks, and 532 (10%) were laboratory-confirmed mixed measles and rubella outbreaks.

Measles Incidence and Measles Virus Genotypes

From 2003 to 2013, annual measles incidence in the region decreased 73%, from 59 to 16 cases per million population. Five countries reported measles incidence of <5 cases per million in 2013, including three (Bhutan, North Korea, and India); 74% of reported cases were in Bangladesh, Bhutan, Nepal, Sri Lanka, and Thailand. By 2013, this regional laboratory network had expanded to include 34 proficient laboratories** with one regional reference laboratory in Thailand. All countries in the region except Timor-Leste had at least one proficient laboratory, including India (nine laboratories), Indonesia (four), and Thailand (13). In addition, Bangladesh, Bhutan, Nepal, Sri Lanka, and Thailand had also started sentinel surveillance for congenital rubella syndrome.

During 2003–2013, a total of 5,680 suspected measles outbreaks were reported in countries in the region, 5,166 (91%) of which were fully investigated.†† Among those investigated, 2,530 (49%) were laboratory-confirmed measles outbreaks, 1,437 (28%) were laboratory-confirmed mixed measles and rubella outbreaks, and 532 (10%) were laboratory-confirmed mixed measles and rubella outbreaks.

** A laboratory that has met defined criteria outlined in the report, “Framework for verifying elimination of measles and rubella” (Wkly Epidemiol Rec 2013;88:89–100, available at http://www.who.int/wer/2013/wer8809/en).
†† A house-to-house survey is conducted in the affected area; ≥5 suspected cases serologically tested for measles/rubella immunoglobulin M; and a case investigation form or line list with basic epidemiologic data is completed.

### TABLE 1. Estimated coverage* with the first and second dose of measles-containing vaccine (MCV), vaccination schedule,† number of reported measles cases,§ and measles cases per 1 million population,¶ by country — World Health Organization (WHO) South-East Asia Region, 2003 and 2013

| Country     | WHO/UNICEF estimated coverage (MCV1: %) | MCV schedule | No. of reported measles cases (JRF)§ | WHO/UNICEF estimated coverage (MCV2: %) | MCV schedule | No. of reported measles cases (JRF)§ | Measles incidence per 1 million population ¶ |
|-------------|----------------------------------------|--------------|--------------------------------------|----------------------------------------|--------------|--------------------------------------|---------------------------------------------|
| Bangladesh  | 67 (MCC) M-9 mos M-18 mos 1,010 0.01 0.16 | —** | 62 —** 4,076 30.6 | 80 (MCC) M-9 mos —** M-15 mos 1,861 88.3 | —** | 0 M-9 mos | 237 1.5 | 22 0.16 |
| Bhutan      | 68 —** M-9 mos —** 0 00.0 | 94 89 —** M-9 mos —** M-24 mos 0 00.0 | 99 99 —** M-9 mos —** M-15 mos 0 00.0 | 42 40 —** M-9 mos —** M-16–24 mos 0 00.0 |
| North Korea | 95 —** M-9 mos —** 0 00.0 | 99 99 —** M-9 mos —** M-24 mos 0 00.0 | 1,010 1.5 | 85 0.05 |
| Indonesia   | 74 21† | M-9 mos M-7 yrs†† 24,457 114.4 | 84 79 M-9 mos —** M-6yr§§ 8,419 33.9 | 74 42 M-9 mos M-16–24 mos 13,822 11.1 | 74 42 M-9 mos M-16–24 mos 13,822 11.1 |
| Maldives    | 86 —** M-9 mos —** 75 267.3 | 99 99 —** M-9 mos —** MMR-18 mos 0 — | 1,010 1.5 | 85 0.05 |
| Myanmar     | 80 —** M-9 mos —** 830 15.6 | 86 80 M-9 mos —** M-18 mos 0 — | 1,010 1.5 | 85 0.05 |
| Nepal       | 75 —** M-9 mos —** 13,344 537.8 | 88 —** M-9 mos —** MMR-18 mos 0 — | 1,010 1.5 | 85 0.05 |
| Sri Lanka   | 99 —** M-9 mos M-12 mo§§ M-MR-3 yrs 65 3.4 | 99 99 M-9 mos M-18 mos 0 — | 1,010 1.5 | 85 0.05 |
| Thailand    | 96 —** M-9 mos MMR-6 yrs 4,519 71.8 | 99 99 M-9 mos MMR-18 mos 0 — | 1,010 1.5 | 85 0.05 |
| Timor-Leste | 55 —** M-9 mos —** 94 110.6 | 70 —** M-9 mos —** 4 3.4 | 1,010 1.5 | 85 0.05 |
| Region overall | 67 6 94,598 58.9 | 78 53 30,101 16.2 | 27 9.7 |

** Abbreviations: M = measles; MR = measles-rubella; MMR = measles-mumps-rubella; UNICEF = United Nations Children’s Fund; JRF = Joint Reporting Form.
†† During 2003–2013, a total of 5,680 suspected measles outbreaks were reported in countries in the region, 5,166 (91%) of which were fully investigated. Among those investigated, 2,530 (49%) were laboratory-confirmed measles outbreaks, 1,437 (28%) were laboratory-confirmed mixed measles and rubella outbreaks, and 532 (10%) were laboratory-confirmed mixed measles and rubella outbreaks.
§§ A laboratory that has met defined criteria outlined in the report, “Framework for verifying elimination of measles and rubella” (Wkly Epidemiol Rec 2013;88:89–100, available at http://www.who.int/wer/2013/wer8809/en).
### FIGURE. Number of reported measles cases* and estimated percentage of children who received their first and second dose of measles-containing vaccine (MCV),† by country — World Health Organization (WHO) South-East Asia Region (SEAR), 2003–2013

** Abbreviations: MCV1 = first dose of MCV in routine immunization; MCV2 = second dose of MCV in routine immunization.
Morbidity and Mortality Weekly Report

TABLE 2. Measles supplementary immunization activities (SIAs),* by country, target age group, type of SIA, and number and percentage of targeted children vaccinated — World Health Organization (WHO) South-East Asia Region, 2003–2013†

| Country     | Year | Vaccine type | SIA type | Extent of SIA | Target age group | Target population | Administrative coverage (%) |
|-------------|------|--------------|----------|---------------|------------------|-------------------|--------------------------|
| Bangladesh  | 2005 | M            | Catch-up | Pilot         | 9 mos–10 yrs     | 1,481,321         | 93                       |
|             | 2006 | M            | Catch-up | National      | 9 mos–10 yrs     | 34,199,900        | >100§                    |
|             | 2010 | M            | Follow-up| National      | 9 mos–5 yrs      | 18,136,066        | 100                      |
| Bhutan      | 2006 | MR           | Catch-up | National      | 9 mos–14 yrs (males) | 338,040 | 98                      |
|             |      |              |          |               | and 15–44 yrs (females) |            |                          |
| North Korea | 2007 | M            | Catch-up | National      | 6 mos–45 yrs     | 16,123,376        | 100                      |
| India       | 2010 | M            | Catch-up | Subnational   | 9 mos–10 yrs     | 10,469,901        | 90                       |
|             | 2011 | M            | Catch-up | Subnational   | 9 mos–10 yrs     | 34,127,013        | 90                       |
|             | 2012 | M            | Catch-up | Subnational   | 9 mos–10 yrs     | 50,134,186        | 90                       |
|             | 2013 | M            | Catch-up | Subnational   | 9 mos–10 yrs     | 36,012,805        | 93                       |
| Indonesia   | 2003 | M            | Catch-up | Subnational   | 6–12 yrs         | 1,030,445         | 95                       |
|             | 2004 | M            | Catch-up | Subnational   | 6–12 yrs         | 2,180,918         | 94                       |
|             | 2005 | M            | Catch-up | Subnational   | 6 mos–15 yrs     | 5,515,324         | 94                       |
|             | 2006 | M            | Catch-up | Subnational   | 6–12 yrs         | 3,161,323         | 96                       |
|             | 2006 | M            | Catch-up | Subnational   | 6 mos–5 yrs      | 3,978,096         | 93                       |
|             | 2007 | M            | Follow-up| Subnational   | 6 mos–5 yrs      | 14,913,092        | 91                       |
|             | 2007 | M            | Catch-up | Subnational   | 6 mos–12 yrs     | 5,473,025         | >100§                    |
|             | 2008 | M            | Follow-up| Subnational   | 1–3 yrs          | 11,203            | 78                       |
|             | 2009 | M            | Follow-up| Subnational   | 9 mos–5 yrs      | 2,124,572         | 92                       |
|             | 2010 | M            | Follow-up| Subnational   | 9 mos–5 yrs      | 3,619,024         | 91                       |
|             | 2011 | M            | Follow-up| Subnational   | 9 mos–5 yrs      | 11,989,559        | 95                       |
| Maldives    | 2005 | MR           | Catch-up | National      | 6–25 yrs (males) | 144,997           | 85                       |
|             |      |              |          |               | and 6–35 yrs (females) |            |                          |
|             | 2006 | MR           | Catch-up | National      | 6–25 yrs (males) | 144,997           | 85                       |
|             |      |              |          |               | and 6–35 yrs (females) |            |                          |
|             | 2007 | MMR          | Catch-up | National      | 4–6 yrs          | 29,529            | 56                       |
| Myanmar     | 2003 | M            | Follow-up| National      | 9 mos–5 yrs      | 2,502,969         | 90                       |
|             | 2004 | M            | Follow-up| National      | 9 mos–5 yrs      | 1,679,487         | 65                       |
|             | 2007 | M            | Follow-up| National      | 9 mos–5 yrs      | 6,056,000         | 94                       |
|             | 2012 | M            | Follow-up| National      | 9 mos–5 yrs      | 6,432,064         | 97                       |
| Nepal       | 2004 | M            | Catch-up | National      | 9 mos–15 yrs     | 5,344,765         | >100§                    |
|             | 2005 | M            | Catch-up | National      | 9 mos–15 yrs     | 4,326,348         | >100§                    |
|             | 2008 | M            | Follow-up| National      | 9 mos–59 mos     | 199,751           | 97                       |
|             | 2008 | M            | Follow-up| National      | 9 mos–59 mos     | 3,903,515         | 93                       |
|             | 2012 | MR           | Catch-up | National      | 9 mos–14 yrs     | 9,579,306         | >100§                    |
| Sri Lanka   | 2003 | M            | Catch-up | National      | 10–15 yrs        | 1,987,847         | 95                       |
|             | 2004 | MR           | Catch-up | National      | 16–20 yrs        | 1,890,326         | 72                       |
|             | 2013 | M            | Catch-up | National      | 6 mos–12m        | 176,587           | 98                       |
| Timor-Leste | 2003 | M            | Catch-up | National      | 9 mos–5 yrs      | 128,318           | 99                       |
|             | 2006 | M            | Catch-up | National      | 6 mos–14 yrs     | 390,687           | 40                       |
|             | 2009 | M            | Follow-up| National      | 9 mos–5 yrs      | 167,136           | 76                       |
|             | 2011 | M            | Catch-up | National      | 6 mos–14 yrs     | 494,427           | 92                       |
| Total       |      |              |          |               |                  | 300,597,935       |                          |

Abbreviations: MCV = measles-containing vaccine; M = measles; MR = measles-rubella; MMR = measles-mumps-rubella.

+ SIAs generally are carried out using two target age ranges. An initial, nationwide catch-up SIA targets all children aged 9 months–14 years, with the goal of eliminating susceptibility to measles in the general population. Periodic follow-up SIAs then target all children born since the last SIA. Follow-up SIAs generally are conducted nationwide every 2–4 years and target children aged 9–59 months; their goal is to eliminate any measles susceptibility that has developed in recent birth cohorts and to protect children who did not respond to the first measles vaccination.

† Data available at http://www.who.int/immunization/monitoring_surveillance/data/en.

§ Values >100% indicate that the intervention reached more persons than the estimated target population.

Maldives) that reported zero cases (Table 1, Figure). In 2013, a total of 248 laboratory-confirmed measles outbreaks and 14 laboratory-confirmed mixed measles and rubella outbreaks were reported in the region. A total of 10,108 confirmed measles cases (laboratory-confirmed and epidemiologically linked) were reported in these outbreaks. The largest proportion of cases (35%) occurred in children aged 1–4 years, followed by children aged 5–9 years (30%), children aged <1 year and persons aged ≥15 years (13% each), and children aged 10–14 years (9%). Of these cases, 68% were in unvaccinated persons. The highest percentage of unvaccinated persons (87%) was in the <1 year age group, followed by the ≥15 years (82%), 10–14 years (71%), 5–9 years (62%) and 1–4 years (61%) age groups.

During 2003–2013, among isolates from patients, measles virus genotypes detected and reported in the region included
D4, D7, and D8 in India; D8, D9, G2, and G3 in Indonesia; D5 in Maldives: D5 and D9 in Myanmar; D4 and D8 in Nepal; D8 in Sri Lanka; and D5, D8, D9, and G2 in Thailand.

Discussion

During 2003–2013, substantial progress was made toward measles control in the South-East Asia Region: through implementation of the regional measles mortality reduction strategies, measles incidence decreased 73% and estimated measles deaths decreased 63% (1,3,7). By 2008, the goal of reducing measles-related deaths by 90% by 2010 from the 2000 baseline was achieved by all countries in the region except India (8,9). After increases in MCV1 and MCV2 coverage and implementation of SIAs, Bhutan, North Korea, and Maldives reported no laboratory-confirmed measles cases in 2013 and might have interrupted endemic measles virus transmission. This apparent success will only be confirmed once the regional verification commission is established and a formal evaluation is conducted, but it indicates that measles elimination in this region is feasible when the current tools and strategies are optimally implemented.

In September 2013, after an extensive review of the progress made and the biologic, programmatic, and financial feasibility of measles and rubella elimination, the 66th session of the Regional Committee of the South-East Asia Region adopted the goal of measles elimination and rubella/congenital rubella syndrome control in the South-East Asia Region by 2020 (1,3), resulting in all six WHO regions now having a measles elimination goal. However, challenges exist to achieving measles elimination in the South-East Asia Region. In 2013, routine MCV1 coverage was <95% nationally for seven of the 11 countries in the region. Of the estimated 21.5 million infants worldwide who did not receive MCV1, almost one third were in India (6.4 million) and Indonesia (0.7 million) (7). In addition, more than half of the SIAs implemented in the region during 2003–2013 did not achieve the target of ≥95% coverage. Information on measles genotypes circulating before measles elimination activities started is important to distinguish indigenous circulating viruses from imported ones, which is required to confirm measles elimination in the region.

The findings in this report are subject to at least two limitations. First, vaccination coverage estimates are derived from administrative data and can be inaccurate because of errors in estimates of target populations or errors in recording doses administered. Second, surveillance data might significantly underestimate actual disease incidence, because not all patients seek care, and not all those who seek care are reported. However, the data on coverage, incidence, and estimated deaths all indicate that measles-associated morbidity and mortality declined considerably in this region during 2003–2013.

What is already known on this topic?

During 1999–2002, coverage with the first dose of measles-containing vaccine in the World Health Organization’s South-East Asia Region increased from 58% to 70%; Sri Lanka and Thailand added a second routine dose of measles-containing vaccine, and 16 million children were vaccinated against measles during supplementary immunization activities (SIAs).

What is added by this report?

During 2003–2013, estimated coverage with the first and second doses of measles-containing vaccine increased from 67% to 78% and from 6% to 53%, respectively, and measles SIAs reached 286 million children. Measles incidence declined by 73%, and estimated measles deaths decreased by 63%. The region adopted the goals of measles elimination and rubella and congenital rubella syndrome control by 2020. All countries in the region conduct some form of case-based measles surveillance, and some countries have implemented sentinel surveillance for congenital rubella syndrome.

What are the implications for public health practice?

To achieve regional measles elimination by 2020, the following are needed: strengthening routine immunization to achieve ≥95% coverage with 2 doses of measles-containing vaccine; optimizing the timing of measles vaccine doses; conducting high-quality SIAs; enhancing surveillance and building on existing laboratory networks; and seeking opportunities for collaboration with other programs.

The adoption of a measles elimination goal in the South-East Asia Region is an opportunity to reenergize efforts and maintain momentum in the region to 1) strengthen routine immunization and achieve ≥95% coverage with MCV2; 2) optimize the timing of MCV1 and MCV2 doses, based on measles epidemiology in each country55, 3) conduct high-quality SIAs; 4) enhance surveillance and build on existing laboratory networks to perform case-based surveillance; and 5) seek opportunities to collaborate with other programs, including use of the measles elimination platform to integrate rubella and congenital rubella syndrome control efforts. As of 2015, all 11 countries in the South-East Asia Region had either developed or were drafting national plans based on the strategies outlined in the Global Measles and Rubella Strategic Plan and the Regional Committee resolution (1,10). With 35 million surviving infants in the region (26% of the global total), the measles elimination goal is a significant opportunity to further decrease measles-related deaths and illness globally by 2020 (7).

55 WHO recommendations on optimal age for administration of first and second MCV doses and interval between doses depends on rate of measles transmission in country and capacity of the health systems. Additional information available at http://www.who.int/wer/2009/wer8435.pdf?ua=1.
References

1. World Health Organization, Regional Committee for the South-East Asia Region. Resolution SEA/RC66/R5: measles elimination and rubella/congenital rubella syndrome control. New Delhi, India: World Health Organization; 2013. Available at http://repository.searo.who.int/bitstream/123456789/16894/1/SEA-RC-66-R5-Measles.pdf.

2. World Health Organization, Regional Office for South East Asia Region. Regional Committee for the South East Asia Region. Report of the 62nd Session, Kathmandu, Nepal, September 2009. SEA/RC62/27. New Delhi, India: World Health Organization; 2009. Available at http://apps.who.int/iris/handle/10665/128481.

3. World Health Organization. Final draft of the report of the Regional Measles Consultation 25–27 August 2009. SEARO, New Delhi. New Delhi, India: World Health Organization; 2009. Available at http://www.who.int/immunization/sage/Draft_report_measles_consultation_01_Sept.pdf.

4. CDC. Progress toward sustainable measles mortality reduction—South-East Asia Region, 1999–2002. MMWR Morb Mortal Wkly Rep 2004;53:559–62.

5. Burton A, Monasch R, Lautenbach B, et al. WHO and UNICEF estimates of national infant immunization coverage: methods and processes. Bull World Health Organ 2009;87:535–41.

6. World Health Organization, Regional Office for South-East Asia Region. Surveillance standards for measles and other priority vaccine-preventable diseases in South-East Asia. Report of the regional workshop. New Delhi, India: World Health Organization; 2013. Available at http://www.searo.who.int/entity/immunization/documents/surv_standars_measles_vpd_2013.pdf.

7. Perry RT, Gacic-Dobo M, Dabbagh A, et al. Progress toward regional measles elimination—worldwide, 2000–2013. MMWR Morb Mortal Wkly Rep 2014;63:1034–8.

8. World Health Organization. Global immunization vision and strategy, 2006–2015. Geneva, Switzerland: World Health Organization; 2005. Available at http://whqlibdoc.who.int/hq/2005/WHO_IVB_05.05.pdf.

9. O’Connor PM, Liyanage JB, Mach O, et al. South-East Asia Regional update on measles mortality reduction and elimination, 2003–2008. J Infect Dis 2011;204(Suppl 1):S396–402.

10. World Health Organization. Global measles and rubella strategic plan: 2012–2020. Geneva, Switzerland: World Health Organization; 2012. Available at http://www.who.int/immunization/newsroom/Measles_Rubella_StrategicPlan_2012_2020.pdf.